

Targeting Human-Cytomegalovirus-Infected Cells by Redirecting T Cells Using an Anti-CD3/Anti-Glycoprotein B **Bispecific Antibody**

Weixu Meng,^{a*} Aimin Tang,^b Xiaohua Ye,^a Xun Gui,^a Leike Li,^a Xuejun Fan,^a Robbie D. Schultz,^a Daniel C. Freed,^b Sha Ha,^b Dai Wang,^b Ningyan Zhang,^a DTong-Ming Fu,^b Zhiqiang An^a

^aTexas Therapeutics Institute, Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center at Houston, Houston, Texas, USA ^bMerck Research Laboratories, Merck & Co., Inc., Kenilworth, New Jersey, USA

Antimicrobial Age

TRANSPORT

AMERICAN SOCIETY FOR

«εσιε •ι»^W eσ ησε elη re «η reη η ι εικrιrη ···ε re αr edate and maching to a tere ed r, ° 0 n. b W y b mak W. bmr c c r c W o color r c om r on mu l polo r n $r_{0} \circ r_{e} \circ \sigma \rightarrow r_{0} \circ r_{0} \circ$ corcolarmolarmolarmolarmolar I - acto co o esta no - rat noora certa ε «_fare (b) σ ε «) r - bv . . . η ε) · σσ ε « for 3) b ·)_f r_{eee} r_{eee} r_{e} r_{e} (e'), re a Mara comebrirra a campirativitatie rabear aca ro er in Wolne I - de ro in vitro. - re or in all de ron, ree e e e e b r - b v vo r e r- γ e e σ r - μ l σ e « « W e - e wing a showing should in a b face accord and a million back to a rn a varvrn. oc o do eeo to re n n a e carb o ca " γe dyeron l staryray be ara.

 $V \sim 1$, $\sigma \in \mathbb{R}$, $r \to pv$, $r \in W$, $r \in \mathbb{R}$, $r \in \mathbb{R}^{f}$, $r \in \mathbb{R}^{f}$ \.r \ r-y

 $\gamma \cdot v r = e^{f} = e^{-i} + e$ -η $r_{n\sigma}$, $r_{r} > 50\%$ r_{r} b f_{r} r_{nb} b N_{o} r_{Mu} I_{r} r_{r} - ite , y of a start in σ object way reneb w tem I -to mul a contration of entration of the array of • $\neg r$) r) r (1, 2).

rors regolance real sarsray bearing roos r

Received 18 August 2017 Returned for modification 7 September 2017 Accepted 10 October 2017

Accepted manuscript posted online 16 October 2017

Citation Meng W, Tang A, Ye X, Gui X, Li L, Fan X, Schultz RD, Freed DC, Ha S, Wang D, Zhang N, Fu T-M, An Z. 2018. Targeting humancytomegalovirus-infected cells by redirecting T cells using an anti-CD3/anti-glycoprotein B bispecific antibody. Antimicrob Agents Chemother 62:e01719-17. https://doi.org/10 .1128/AAC.01719-17.

Copyright © 2017 Meng et al. This is an openaccess article distributed under the terms of the Creative Commons Attribution 4.0 International license.

Address correspondence to Tong-Ming Fu, tong-ming_fu@merck.com, or Zhiqiang An, Zhigiang.An@uth.tmc.edu.

* Present address: Weixu Meng, Division of Hematopoietic Stem Cell and Leukemia Research, Gehr Family Center for Leukemia Research, City of Hope, Duarte, California, USA.

r an etti b a mares w

 r_{α} -b b r_{α} - r_{α} - rγr δ δ σ'γδ r. c c c ec' < c ◄ b e = coo κ r i I κ σ γ c < mo κ r $\begin{array}{c} \mathbf{r} = \mathbf$ ι τ δ . η. ι ε be e η eb b. e= σσ κ ω Ι · · e. τη ι b baciae · · σι $e^{i\eta_{\alpha_{1}}}\sigma \quad e^{-i\eta_{1}} e^{-i\eta_{1}} e^{-i\eta_{1}} e^{-i\eta_{1}} e^{i\eta_{1}} e^{-i\eta_{1}} e^{-i\eta_{1}}$ baciacoleca ·)) b m mesol ce. r mol no) re & () m m e e b e r me e r. beowniberre reiw ore i nebreneis. b bis erer re a maga alybar a care i a w be a boar a maga ana i ana i ranena γ the least brack for a range are end of the source of th on or the bill no to con bolk ring cor on really being really bolk ring. nneppertebel " to voo n to to to to to to to to to eferer), r-porte e boebibbeeneb.) r-po) ε_Fe_F^r^m ^W ¹⁰⁰ ^K ε ε_Fε ε ^{rel}^m ^eε \^a ^K ^r^m ^K ^e⁻ ^Γ ^aε ε^aε ^r^m ^(⁻) egerer r r, r-n-eng, refo ege kb W ι ····· σ_er-a_en ι r W ··· n e $\mathbf{u} \quad \mathbf{I} = \mathbf{e}_{\mathbf{r}_{\mathbf{r}}} \mathbf{e}_{\mathbf{r}} \mathbf{e}_{\mathbf$ $w r_{-1} \uparrow_{r'} \uparrow_{w} \downarrow_{w} \downarrow_{w}$ «¬• eq to) r • o o o o o r o r o b) to o « « « « v r-r-r « w) ty l - o o to Ketreo (11) neevee o olen towe also an efter of enve y b bol a r r m a m r on ol m a m σσ ξ aν y oh a r o et m r σ (o m r) σ et $\sigma = r + \sigma^{2} + \sigma^{2$ «mak reem r. r. oc alle to be «) ar seelas male «mare» to w ົ່າຈາງເປັ້ເຈະ້າຫຼາງ ໆ ຕໍ່ເປັນ ປະ ປະຕິ ເເ ຊີ່ເຕົາ, 5 ເ $\log w r_{n}$ $b = \frac{1}{2} c_{n} b$ (12, 14).Intitan al acor bit of the other of the terminant of the other othe


(a) 7 + ¹7

Jegred I - to to wieber et co

^ A	FRÍ-IMGT	Combined	FR2-IMGT	Combined
	(1-26)	CDR1	(39-55)	CDR2
ADSVK.G IGHV3-53*04 EV ADSVK.G 272 ZH_ OS FGTT YYASWVN GL 2	T FESGGLGLVOBLGGST KLS	CKAS GEDYLL LYSSYN.	MSWVROAR GKGTENIGY	IDRVILFGTTL XY
		FR3-IMGT (66-104)	Combined CDR3	(118-128)
ŴTVSS WTVSS WTVSS		ISSHNAQ NTLYLQLNSI	RA EDTAVYYC AR TOU JTA ADTATYFC ATNTHG .RA EDTAVYFC <mark>ATNTHG</mark>	.TGGYYL WGPGTL
Combined CDR2		FR1-IMGT (1-26)	Combined CDR1	FR2-IMG1 (39-55)
.PKLLIY AAS SLQSG PKLLIY AAS NLASG QQKP GKPPK <mark>LLIY AA</mark>	VP.S 272.7K ELD	MTQSPSSVSASV GDRVI MTQTPASVSEPV GGTVI	PITORAS QGISS PIKOQAS QSIGS SV-GDRVTIKO <mark>QAS QSI</mark>	W LAWYQQKP GKA N LAWYQQKP GQP
FR4-IMGT (118-128)			R3-IMGT 66-104)	Combined CDR3
T FGGGTKVEIK. .LNNA FGGGTEVVVK. .TNNALWAA FUUSIKVEIN.		272.7K RFKGSGS	FTLTISSLQP EDFATYY GTQFTLTISGVQC DDA GTDFTLTISSLOP EDF	ATYYC QCNYY
E	-2 Hundre		ين 50000 - 	
10 ⁻² 10 ⁻¹ 10 ⁰ 10 ¹ 1 concentration (ug/ml)		bay? bay? bay	• 10	⁻⁵ 10 ⁻⁴ 10 ⁻³ Antibody c

1 + r/H N, $r_{1} = -1$ K, $w = r_{1} = r_{1}$ e^f e^f e^f (17, 1). r = -pv 272.7 K b r, 1 = 1 w $r_{1} = -1$ r, r = -pv, 272.7, $r_{2} = -pv$ $r_{1} = -1$ r, $r_{2} = -1$

-marce σ en r_{1} r_{2} r_{2}



 $\begin{array}{c} \mathbf{2} \quad \mathbf{0} \quad \mathbf{e}^{f} \quad \mathbf{b} \quad \mathbf{1} \quad \mathbf{1} \quad \mathbf{e}^{f} \quad$


bywg 1, 2, 3, b 4 or war - oo - e. 1 w I - war b N - 1 ago o. n. b. e. e. je v . o e. o . n . h. b. con bre to ro a re $\sigma = 1 \sigma_{e}^{-1} \sigma_{$


 $b_{\sigma} = b_{\sigma} b_{\sigma} b_{\sigma} + r_{\sigma} + n_{\sigma} + n_{\sigma} + n_{\sigma} + r_{\sigma} +$ $\kappa = r = 3, b = w = \sigma e^{b} r + r = \sigma e^{-r} e^{-r} = \pi b^{-1} e^{-r} \sigma^{-r} e^{-r} e$

 $\mathbf{a}_{\mathbf{r}},\mathbf{r}_{\mathbf{n}}$ \mathbf{u} 23. $\mathbf{\sigma}$. $\mathbf{e}_{\mathbf{r}},\mathbf{n}_{\mathbf{r}},\mathbf{r}_{\mathbf{r}},\mathbf{b}_{\mathbf{r}},\mathbf{e}_{\mathbf{r}},\mathbf{b}_{\mathbf{r}}$ $\mathbf{e}_{\mathbf{r}},\mathbf{r}_{\mathbf{r}}$ $\mathbf{e}_{\mathbf{r}},\mathbf{r}_{\mathbf{r}}$ $\mathbf{e}_{\mathbf{r}},\mathbf{r}_{\mathbf{r}}$

 $\begin{array}{c} \mathbf{v} = \mathbf{v} + \mathbf$


 $1 e^{f}r_{1}$.





 $Y_{k}b \quad r_{k} = I - I_{k} + k b \quad N - 1 + e \sigma + r_{k} \sigma \quad e + k b \sigma e^{f} + N + e^{f} + e \sigma + I_{k} + r_{k} + r_{$

to W, cc) 1 6 b r. c m ~ 1 è co el me ~ 1 ~ 1 r m 1 el f ec e e 4, 6 кы I - Карр N-1 кол r ⊷¦pv C C C' ") "**C** O neb, e^e hebo hee oon are reversion 100 25, b 6 b 107 (e.3 r m et). - m r w, r oc ... eo r, b, es ۱^r m r د ۲ کس^ا Vier e ob mer e or e mere o 6 107 yo be rarbon w regenerated I - darbo, N-1 ago, ar darbo, N-1 ago, i e 3 r. a e), a by range r w b and r r b ry r



P N.

 $\begin{array}{c} \neg_{1} \zeta \ r_{1} \cdot r_{1} \cdot r_{1} & | \\ \neg_{1} \cdot r_{1} \cdot r_{1} \cdot r_{1} \cdot r_{1} \cdot r_{1} & | \\ \neg_{1} \cdot r_{1} \cdot$

a share alm I - dente baca a crete bran an real of the all of elerry, r c c c c raberer one o a reo eler l - elerto N-1 . o win win win win with the second of the on the one of the o eparnyb -α eparnyb be bernul eary (.e.3). b, real W . You and reaction your y one reaction of the reaction rochanacolman ann anrairco wan crealmarc bre e.

[(y + y)] = (y + y) =

 $+ \sigma r$ r σ + 1 r σ + 1 r σ + 1 r σ + 1 r σ + 1 r σ + 1 r σ + 1 r r σ + 1 r σ + 1 r rσ + 1 σcheres in cert rog (36), breech rog r. Nieceice begroeb • ∩₀ ∾ (37).

σ r s e^{-1} r q s e^{-1} r e^{-1} r q r e^{-1} r -3') b 366 - (5'-366 - (5'-

-3'), 407 - (5'-

-3'), b 407 - (5'--3), b 40/ τ , (5)--3), b 40/ τ , (5)--3), c $r \in [r_{2.1}, 0]$, $r \in [r_{2.1}, 1]$, $r \in [r_{2.1}, 1$ $r \rightarrow pv$ 272.7 $e^{-r/r} = (rr_{0} / r \rightarrow pv \cdot r_{0} + r$

n b. e. n brng.

· ι ε b olmo 1.5. r. σε a 30 mb ι r - bv rrar no σ κ r ε r 10 με/ . Νι το ε ε ιο ε b ι ο ε $(\mathbf{w}, \mathbf{N}) = (\mathbf{w}, \mathbf{N}) + (\mathbf{w$ $bb_{e}b = -3r_{m}5$ $\gamma r 100 \mu_{e}e e r_{m}e_{e}^{2}e b k e \sigma - (\gamma r) + -\gamma e r_{b}r_{m} + -\gamma r_{m}r_{m}r_{m}$, rr e e Ng 5.

N, 5%. , b 0.05% , 3). σ (1 × 10⁶) σσξ b η 1. γr4. r 1 μe/ 1. 272.7 $-1\mu e/\sigma c^{*} + \gamma r - pv$. $c\sigma cc v c b r c N y b cc r c y b r 1 \mu e/$

). $e^{i\theta}e^{i\theta} = 1$ $r^{i\theta}\sigma^{i\theta}$ $e^{i\theta}e^{i\theta}e^{i\theta}$ $b^{i\theta}e^{i\theta}\sigma^{i\theta}e^{i\theta}$

 $\begin{array}{c} \mathbf{x} & \mathbf{y} & \mathbf{z} & \mathbf$

- ,N - 124.

 $= \frac{r_1}{r_1} = \frac{r_2}{r_1} = \frac{r_1}{r_2} + \frac{r_2}{r_1} = \frac{r_2}{r_2} + \frac{r_2}{r_2} = \frac{r_2}{r_1} + \frac{r_2}{r_2} = \frac{r_2}{r_2} = \frac{r_2}{r_2} + \frac{r_2}{r_2} = \frac{r_2}{r_2}$

·σ mi vo vori beb wleev-ever e-mirev mereliev r.m.

oorby you bebwes but less & mrs. mr. , , re

 $e^{f}e^{f}e^{f}$, $\eta \eta e^{f}$, b, b r, η and η by r η (ef r -0042-< \o 20030616).

- 1. $bb_{eq} r_{m} | , N_{1}, m_{3}, \dots, m_{s} | , 1 = 1 = 1 = 7.$ $h \to \sigma = \frac{1}{2} r_{m} + \frac{$

- o• • • .115 545.
- 11. r_{σ} r_{σ}
- 13. I_{a} , r_{a} , r_{a}
- 14. $b \in \{w, N_0, r_{\pm}, r_{\pm$
- $17. \qquad e_{f} = 1316517110.$

- 10.103 / r.2621.
- 22. (1, 1) = 1, rr =-.01 57-16.
- N, rr, r
- 25. $\gamma = 0$, r = 0, r = 0
- - 73 -3
- 27. N (n_{1}) (n_{1}) (n_{2}) (n_{2}) b n.me/10.115 /107 -0432. , -15-0612.
- $\sum_{n=1}^{n} \frac{e^{-10.115}}{10^{-0432}} \frac{15-0612}{100} \frac{10}{100} \frac{10}{1$
- 30.
- 31.
- LN YW 2314.
- . rr₀, //₂ , e/10.1002/ . .24237.

 $e^{f_{m}}$ N_{m} r_{r} b 110,270,275. rr_{σ}/b_{m} $e^{f_{10}}$ $1073/v_{\sigma}$.121 17110.

- n 642 22 2 31.

- 3. $[e^{f}, -e^{f}, -$

- 42. $(1, 1) \in [1, 1]$, (1, 2) = [1, 2], (1, 2)
- 43. (1, 2, 3, 3, 4, 5, 1,
- 012